Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?
Aged
Aged, 80 and over
Bone Neoplasms
/ diagnostic imaging
Bone and Bones
/ diagnostic imaging
Edetic Acid
/ analogs & derivatives
False Negative Reactions
False Positive Reactions
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Middle Aged
Oligopeptides
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms
/ diagnostic imaging
68 Ga-PSMA
Bone
Cancer
PET/CT
Prostate
Scintigraphy
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
23
03
2020
accepted:
26
04
2020
pubmed:
13
5
2020
medline:
28
5
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
We aimed to evaluate the role of bone scintigraphy (BS) which has long been the imaging modality of choice in prostate cancer (PCa) and performed a head-to-head comparison between BS, BS + SPECT/CT and 68 Ga-PSMA-PET/CT, for the detection of bone metastasis of PCa. We evaluated 138 PCa patients who underwent BS and 68 Ga-PSMA PET/CT and SPECT/CT of 102 of 138 patients. Images were interpreted retrospectively and areas of abnormally increased tracer uptake related to PCa were documented as benign, metastatic or equivocal. Equivocal uptakes were finally diagnosed based on a consensus review of correlative imaging. Patient- and lesion-based analysis was performed. Patients with superscan images were excluded from lesion-based analysis. At least one metastatic or equivocal uptake in skeleton was defined in 76 of 138 (55%) BS, in 33 of 102 (32.3%) SPECT/CT, and in 49 of 138 (35.5%) 68 Ga-PSMA PET/CT. 23 (16.7%) patients had also superscan findings on BS and 68 Ga-PSMA PET/CT. For patient-based analysis, sensitivity, specificity, accuracy, PPV, and NPV were calculated as 91.1%, 64.5%, 73.1%, 55.4% and 93.7% for BS; 95.5%, 82.7%, 86.9%, 72.8% and 96.2% for BS + SPECT/CT; 97.7%, 95.7%, 95.6%, 91.6% and 98.8% for 68 Ga-PSMA PET/CT. For lesion-based analysis, sensitivity, specificity, accuracy, PPV, and NPV were 53%, 63.9%, 60.1%, 42.8% and 71.8% for BS; 59.2%, 87.6%, 77.7%, 62.6% and 80% for BS + SPECT/CT; 96.4%, 98.1%, 97.5%, 96.4% and 98.1% for 68 Ga-PSMA PET/CT. This study has shown that 68 Ga-PSMA PET/CT overcomes the limitations of BS and proves superiority in detecting bone metastases, even in patients with SPECT/CT. Our findings present important implications that 68 Ga-PSMA PET/CT can replace BS in future practice.
Identifiants
pubmed: 32394269
doi: 10.1007/s12149-020-01474-7
pii: 10.1007/s12149-020-01474-7
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-485Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA. 2017;67(1):7–30.
pubmed: 28055103
Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164–87.
pubmed: 24120180
doi: 10.1016/j.ejca.2013.09.002
Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.
pubmed: 10836297
doi: 10.1053/hp.2000.6698
Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8(6):357.
pubmed: 21556025
doi: 10.1038/nrclinonc.2011.67
Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, et al. North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. Bone. 2018;194(98):4.
Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.
pubmed: 23974666
doi: 10.1007/s00259-013-2532-6
Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KM, Moshokoa E, et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin cancer. 2018;16(5):392–401.
pubmed: 30120038
doi: 10.1016/j.clgc.2018.07.009
Pollen JJ, Witztum K, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol. 1984;142(4):773–6.
doi: 10.2214/ajr.142.4.773
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.
pubmed: 9763084
doi: 10.1016/S0090-4295(98)00278-7
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.
pubmed: 28497198
pmcid: 5486817
doi: 10.1007/s00259-017-3711-7
Yaxley JW, Raveenthiran S, Nouhaud F-X, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. Bju Int. 2019;124(3):401–7.
pubmed: 31141284
doi: 10.1111/bju.14828
Haran C, McBean R, Parsons R, Wong D. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: a retrospective review in a private centre. J Med Imaging Radiat Oncol. 2019;63:495–9.
pubmed: 30972933
doi: 10.1111/1754-9485.12885
Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU-EANM-ESTRO-ESUR-SIOG. Eur Urol. 2019;76:790–813.
pubmed: 31587989
doi: 10.1016/j.eururo.2019.09.020
Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31(9):709–17.
pubmed: 28900854
doi: 10.1007/s12149-017-1207-y
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, et al. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med. 2018;32(8):512–22.
pubmed: 30109562
pmcid: 6182628
doi: 10.1007/s12149-018-1291-7
Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ. 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging. 2018;38(6):911–22.
doi: 10.1111/cpf.12480
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114–211.
pubmed: 27290607
doi: 10.1007/s00259-016-3435-0
Janssen J-C, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, et al. Comparison of hybrid 68 Ga-PSMA-PET/CT and 99m Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. Eur Radiol. 2018;28(2):610–9.
pubmed: 28779400
doi: 10.1007/s00330-017-4994-6
Artigas C, Alexiou J, Garcia C, Wimana Z, Otte F, Gil T, et al. Paget bone disease demonstrated on (68) Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(1):195–6.
pubmed: 26502983
doi: 10.1007/s00259-015-3236-x
De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, et al. Fibrous dysplasia mimicking bone metastasis on 68 GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44(9):1607–8.
pubmed: 28488027
doi: 10.1007/s00259-017-3712-6
Jochumsen MR, Madsen MA, Gammelgaard L, Bouchelouche K. Lumbar Osteophyte Avid on 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med. 2018;43(6):456–7.
pubmed: 29538033
doi: 10.1097/RLU.0000000000002065
Jochumsen MR, Dias AH, Bouchelouche K. Benign traumatic rib fracture: a potential pitfall on 68Ga-prostate-specific membrane Antigen PET/CT for prostate cancer. Clin Nucl Med. 2018;43(1):38–40.
pubmed: 29076907
doi: 10.1097/RLU.0000000000001871
Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–34.
pubmed: 8753752
doi: 10.1016/S0090-4295(96)00184-7
Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2045–54.
pubmed: 29980832
pmcid: 6182397
doi: 10.1007/s00259-018-4079-z
Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41(6):2087–92.
pubmed: 23041906
pmcid: 3583693
doi: 10.3892/ijo.2012.1649
Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33(10):766–75.
pubmed: 31338731
doi: 10.1007/s12149-019-01387-0
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester H-J, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962–8.
pubmed: 28522740
doi: 10.2967/jnumed.117.193581
Yuminaga Y, Rothe C, Kam J, Beattie K, Arianayagam M, Bui C, et al. 68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy. Asian J Urol. 2020. https://doi.org/10.1016/j.ajur.2020.02.001 .
doi: 10.1016/j.ajur.2020.02.001
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF, editors. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic oncology: Seminars and Original Investigations. Amsterdam: Elsevier; 1995.
Soydal C, Nak D, Araz M, Akkus P, Urun Y, Ozkan E, et al. Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma. Nucl Med Commun. 2019;40(12):1243–9.
pubmed: 31688499
doi: 10.1097/MNM.0000000000001106
Simsek DH, Sanli Y, Kuyumcu S, Engin MN, Buyukkaya F, Demirci E. Clinical impact of lower limb imaging in 68Ga-PSMA PET-CT for patients with prostate cancer. J Nucl Med Technol. 2019. https://doi.org/10.2967/jnmt.118.224303 .
pubmed: 31019043
doi: 10.2967/jnmt.118.224303
Morigi JJ, Anderson J, Fanti S. Promise of PET imaging in prostate cancer: improvement or waste of money? Curr Opin Urol. 2020;30(1):9–16.
pubmed: 31652164
doi: 10.1097/MOU.0000000000000684